{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:55:24Z","timestamp":1791093324278,"version":"4.1.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,10,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bosutinib, a dual Src\/Abl kinase inhibitor, has shown potent activity against chronic myeloid leukemia (CML). In this phase 1\/2 study we evaluated bosutinib in patients with chronic phase imatinib-resistant or imatinib-intolerant CML. Part 1 was a dose-escalation study to determine the recommended starting dose for part 2; part 2 evaluated the efficacy and safety of bosutinib 500 mg once-daily dosing. The study enrolled 288 patients with imatinib-resistant (n = 200) or imatinibintolerant (n = 88) CML and no other previous kinase inhibitor exposure. At 24 weeks, 31% of patients achieved major cytogenetic response (primary end point). After a median follow-up of 24.2 months, 86% of patients achieved complete hematologic remission, 53% had a major cytogenetic response (41% had a complete cytogenetic response), and 64% of those achieving complete cytogenetic response had a major molecular response. At 2 years, progression-free survival was 79%; overall survival at 2 years was 92%. Responses were seen across Bcr-Abl mutants, except T315I. Bosutinib exhibited an acceptable safety profile; the most common treatment-emergent adverse event was mild\/moderate, typically self-limiting diarrhea. Grade 3\/4 nonhematologic adverse events (&gt; 2% of patients) included diarrhea (9%), rash (9%), and vomiting (3%). These data suggest bosutinib is effective and tolerable in patients with chronic phase imatinib-resistant or imatinib-intolerant CML. This trial was registered at http:\/\/www.clinicaltrials.gov as NCT00261846.<\/jats:p>","DOI":"10.1182\/blood-2011-05-355594","type":"journal-article","created":{"date-parts":[[2011,8,24]],"date-time":"2011-08-24T23:15:38Z","timestamp":1314227738000},"page":"4567-4576","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":393,"title":["Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome\u2013positive chronic myeloid leukemia patients with resistance or intolerance to imatinib"],"prefix":"10.1182","volume":"118","author":[{"given":"Jorge E.","family":"Cortes","sequence":"first","affiliation":[{"name":"M. D. Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"M. D. Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[{"name":"Universit\u00e4ts-Klinikum Aachen, RWTH Aachen, Germany;"},{"name":"Universit\u00e4ts-Klinikum Hamburg-Eppendorf, Hamburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wook","family":"Kim","sequence":"additional","affiliation":[{"name":"Seoul St Mary's Hospital, Seoul, South Korea;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna G.","family":"Turkina","sequence":"additional","affiliation":[{"name":"Hematology Research Center, Moscow, Russia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Xiang","family":"Shen","sequence":"additional","affiliation":[{"name":"Ruijin Hospital, Shanghai, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Pasquini","sequence":"additional","affiliation":[{"name":"Hospital das Cl\u00ednicas da Universidade Federal do Paran\u00e1, Paran\u00e1, Brazil;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Jean","family":"Khoury","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Arkin","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Volkert","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Besson","sequence":"additional","affiliation":[{"name":"Pfizer Global Research and Development, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richat","family":"Abbas","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Collegeville, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Leip","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Collegeville, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Gambacorti-Passerini","sequence":"additional","affiliation":[{"name":"University Milano Bicocca, Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111813115073800_B1","unstructured":"National Comprehensive Cancer Network\n          NCCN Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia. V. 2.2009.\n          Accessed May 12, 2009\n          \n            http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/cml.pdf"},{"key":"2019111813115073800_B2","volume-title":"Cancer Facts & Figures, 2010","author":"American Cancer Society","year":"2010"},{"issue":"10","key":"2019111813115073800_B3","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"6","key":"2019111813115073800_B4","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","article-title":"Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.","volume":"22","author":"Hochhaus","year":"2008","journal-title":"Leukemia"},{"issue":"20","key":"2019111813115073800_B5","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"issue":"24","key":"2019111813115073800_B6","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111813115073800_B7","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"issue":"12","key":"2019111813115073800_B8","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"19","key":"2019111813115073800_B9","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"issue":"24","key":"2019111813115073800_B10","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111813115073800_B11","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"23","key":"2019111813115073800_B12","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111813115073800_B13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1634\/theoncologist.2007-0170","article-title":"Therapy options in imatinib failures.","volume":"13","author":"Ramirez","year":"2008","journal-title":"Oncologist"},{"issue":"5","key":"2019111813115073800_B14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc2126","article-title":"Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.","volume":"7","author":"Weisberg","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"18","key":"2019111813115073800_B15","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1002\/cncr.24504","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"issue":"4","key":"2019111813115073800_B16","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"issue":"23","key":"2019111813115073800_B17","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","article-title":"In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.","volume":"66","author":"Puttini","year":"2006","journal-title":"Cancer Res"},{"issue":"2","key":"2019111813115073800_B18","first-page":"375","article-title":"SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.","volume":"63","author":"Golas","year":"2003","journal-title":"Cancer Res"},{"issue":"3","key":"2019111813115073800_B19","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/leu.2008.334","article-title":"Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.","volume":"23","author":"Remsing Rix","year":"2009","journal-title":"Leukemia"},{"issue":"4","key":"2019111813115073800_B20","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2007-05-092056","article-title":"Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src\/Abl kinase inhibitor SKI-606.","volume":"111","author":"Konig","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2019111813115073800_B21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood-2003-05-1535","article-title":"Inhibitory effect of imatinib on normal progenitor cells in vitro.","volume":"103","author":"Bartolovic","year":"2004","journal-title":"Blood"},{"issue":"3","key":"2019111813115073800_B22","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants.","volume":"27","author":"Redaelli","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111813115073800_B23","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"2019111813115073800_B24","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.3238.3238","article-title":"Nilotinib in chronic myeloid leukemia patients in chronic phase (CMLCP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study.","volume":"112","author":"Kantarjian","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2019111813115073800_B25","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1182\/blood-2008-09-180604","article-title":"Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia.","volume":"114","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"key":"2019111813115073800_B26","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1538-7836.2009.03369.x","article-title":"The Y's that bind: negative regulators of Src family kinase activity in platelets.","volume":"7","author":"Newman","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2019111813115073800_B27","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1182\/blood-2009-02-205328","article-title":"The new tyrosine-kinase inhibitor and anti-cancer drug dasatinib reversibly affects platelet activation in vitro and in vivo.","volume":"114","author":"Gratacap","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2019111813115073800_B28","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/1078-0432.CCR-07-4175","article-title":"Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.","volume":"14","author":"Brave","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2019111813115073800_B29","first-page":"228","article-title":"Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate.","volume":"5","author":"Scheinfeld","year":"2006","journal-title":"J Drugs Dermatol"},{"issue":"25","key":"2019111813115073800_B30","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.","volume":"25","author":"Quint\u00e1s-Cardama","year":"2007","journal-title":"J Clin Oncol"},{"issue":"29","key":"2019111813115073800_B31","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.2174\/092986708786848578","article-title":"Targeted drugs in chronic myeloid leukemia.","volume":"15","author":"Gora-Tybor","year":"2008","journal-title":"Curr Med Chem"},{"key":"2019111813115073800_B32","volume-title":"SPRYCEL (dasatinib) tablet for oral use [package insert]","year":"2009"},{"key":"2019111813115073800_B33","volume-title":"GLEEVEC (imatinib mesylate) tablets for oral use [package insert]","year":"2009"},{"issue":"2","key":"2019111813115073800_B34","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3324\/haematol.11680","article-title":"Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib.","volume":"93","author":"Franceschino","year":"2008","journal-title":"Haematologica"},{"key":"2019111813115073800_B35","article-title":"A single dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of bosutinib (SKI-606) on cardiac repolarization in healthy adult subjects.","author":"Abbas"},{"key":"2019111813115073800_B36","volume-title":"Tasigna (nilotinib) [package insert]","year":"2007"},{"issue":"4","key":"2019111813115073800_B37","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.","volume":"111","author":"le Coutre","year":"2008","journal-title":"Blood"},{"key":"2019111813115073800_B38","article-title":"Bosutinib: a novel dual Src\/Abl kinase inhibitor.","volume-title":"Small Molecules in Oncology, Recent Results in Cancer Research","author":"Keller","year":"2010"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/17\/4567\/1463749\/zh804311004567.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/17\/4567\/1463749\/zh804311004567.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T13:36:41Z","timestamp":1574084201000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/17\/4567\/29063\/Safety-and-efficacy-of-bosutinib-SKI606-in-chronic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,27]]},"references-count":38,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2011,10,27]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-05-355594","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,27]]}}}